Primary Diffuse Large B-Cell Lymphoma of the CNS · line 1 · R-MPV (Rituximab + HD-Methotrexate + Procarbazine + Vincristine), 5 cycles q14d
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-R-MPV |
| ID | IND-PCNSL-1L-R-MPV |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-PCNSL |
| Sources | SRC-NCCN-BCELL-2025 SRC-NCCN-CNS-2025 |
Notes
STUB. Default для Ukrainian context — більш доступний за MATRix.
Used By
Algorithms
ALGO-PCNSL-1L- ALGO-PCNSL-1L
Contraindications
CI-RENAL-FAILURE-FOR-HD-MTX- CI-RENAL-FAILURE-FOR-HD-MTX